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Human induced pluripotent stem cells (hiPSCs) are of high interest because they can be differentiated into a vast range of different
cell types. Ideally, reprogrammed cells should sustain long-term culturing in an undifferentiated state. However, some
reprogrammed cell lines represent an unstable state by spontaneously differentiating and changing their cellular phenotype and
colony morphology. This phenomenon is not fully understood, and no method is available to predict it reliably. In this study,
we analyzed and compared the proteome landscape of 20 reprogrammed cell lines classified as stable and unstable based on
long-term colony morphology. We identified distinct proteomic signatures associated with stable colony morphology and with
unstable colony morphology, although the typical pluripotency markers (POU5F1, SOX2) were present with both morphologies.
Notably, epithelial to mesenchymal transition (EMT) protein markers were associated with unstable colony morphology, and
the transforming growth factor beta (TGFB) signalling pathway was predicted as one of the main regulator pathways involved
in this process. Furthermore, we identified specific proteins that separated the stable from the unstable state. Finally, we assessed
both spontaneous embryonic body (EB) formation and directed differentiation and showed that reprogrammed lines with an
unstable colony morphology had reduced differentiation capacity. To conclude, we found that different defined patterns of
colony morphology in reprogrammed cells were associated with distinct proteomic profiles and different outcomes in
differentiation capacity.
1. Introduction
Human pluripotent stem cells (hPSCs) such as induced
pluripotent stem cells (iPSCs) and embryonic stem cells
(ESCs) have the potential to be differentiated into a whole
range of different cell types and are, therefore, of high interest
for both researchers and clinicians. Reprogramming of
somatic cells to generate hiPSCs has rapidly gained popu-
larity as it enables the use of patient-specific cells.
Maintaining cells in a pluripotent state in vitro requires
routine monitoring during expansion. A typical characteriza-
tion pipeline to ensure pluripotency includes expression of
singular pluripotency markers (SOX2 and POU5F1), karyo-
type analysis, and the ability to form the three germ layers
using teratoma assays or embryoid body formation [1].
Despite these quality controls, numerous studies have shown
major line-to-line variations [2–5]. To improve the utility of
hPSCs in regenerative medicine and to ensure high-quality
clinical-grade cell products, we need a pipeline of robust
quality control methods that can be automated to benchmark
the cells and filter out reprogrammed cells of inferior quality.
Besides teratoma formation, the colony morphology of
reprogrammed cells is considered an important assessment
criterion of pluripotency [6–10]. In several studies, the capac-
ity to form teratomas and stable culturing has been correlated
to colony morphology [6, 11–13], thus correlating this aspect
with the functionality of the hiPSC. However, during long-
term culturing, the colony morphology has been observed
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to vary in basically two forms: stable and unstable colony
morphologies. Typically, a reprogrammed cell line with a
stable colony morphology exhibits compact colonies, usually
round, with distinct borders and well-defined sharp edges
and is associated with a pluripotent state [14]. A repro-
grammed cell line with an unstable colony morphology
exhibits irregular colony morphology and is associated with
spontaneous differentiation [9]. Although colony morphol-
ogy is an important indicator of pluripotency, it suffers from
subjective evaluation and lack of well-established quantitative
metrics. Several groups have in recent years established met-
rics of colony morphology based on image acquisition to
probe for loss of pluripotency [8, 15]. However, this requires
sophisticated microscopy methods and only takes into
account the physical characteristics of the cells and colonies.
Proteomics provides an excellent tool for large-scale
quantification and benchmarking of cells and an opportunity
to further improve the characterization of colony morphol-
ogy of reprogrammed cells. Compared to other ~omics
approaches (transcriptomics and genomics), proteomics mea-
sures the translated proteins as opposed to molecules that
potentially can become the proteins [16]. The proteome is
dynamic and changes rapidly. In this study, we hypothesized
that the proteome of reprogrammed cell lines showing stable
colony morphology would differ from reprogrammed cell
lines showing unstable colony morphology. Subsequently, we
aimed to use proteomics to obtain insight into the molecular
landscape associated with different colonymorphology groups
and corresponding variable differentiation potential.
2. Materials and Methods
2.1. Cell Source. We reprogrammed fibroblasts taken from
seven donors. All patients gave written informed consent.
The reported experiments were approved by the Regional
Committee of Medical and Health Research Ethics (REK
2010/2295). All methods were performed according to the
Declaration of Helsinki. A total of 20 reprogrammed cell
lines were generated. From donor 1, we generated the follow-
ing reprogrammed cell lines; 1-A, 1-B, and 1-C. Furthermore,
cell lines 2-A, 2-B, and 2-C are derived from donor 2; cell
lines 3-A, 3-B, 3-C, and 3-D are derived from donor 3; cell
lines 4-A, 4-B, and 4-C are derived from donor 4; cell lines
5-A and 5-B are derived from donor 5; cell lines 6-A, 6-B,
and 6-C are derived from donor 6, while cell lines 7-A and
7-B are derived from donor 7. Additional information can
be found in supplementary table 1.
2.2. Episomal Reprogramming. Reprogramming of fibro-
blasts from donors 1-4 was performed by using episomal
reprogramming [17] with vectors from Addgene: #27077
(OCT3/4), #27080 (L-MYC, LIN28), and #27078 (SOX2,
KLF4). The plasmids were expanded in bacterial culture
and purified using the QIAfilterMidi Kit (cat# 12243, Qiagen).
The inserted genes were verified with PCR using the primers
pCAG-F (GCAACGTGCTGGTTATTGTG) and WPRE-R
(CATAGCGTAAAAGGAGCAACA). Fibroblast cells were
reprogrammed using the Amaxa NHDF Nucleofector Kit
(cat# VAPI-1001, Lonza). Fibroblast cells were harvested with
trypsin (0.25%), and 500,000 cells were dissolved in 100μL
Amaxa NHDF Solution together with 1μg of each plasmid.
The plasmids were delivered to the cells by electroporation
(Nucleofector™ 2b Device) and plated in MEF media
(DMEM, 10% FBS, 1% L-glutamine, 1% minimum essential
medium nonessential amino acid (MEM-NEAA), 1% Sodium
Pyruvate). At day six, the fibroblasts were split 1 : 6, and from
day seven, a knockout serum replacement- (KOSR-) based
hESC medium (DMEM-F12, 20% KOSR, 1% MEM-NEAA,
1% GlutaMAX, and 1% Penicillin-Streptomycin (P/S)) was
used. Clearance of the episomal plasmids was observed at
day 13 after transfection, by disappearance of the GFP-
tagged control vector. Media were changed daily until pickable
colonies emerged by 21-26 days post transfection. Two to four
different colonies per donor were picked and expanded in
mTeSR™1 media (cat# 85850, STEMCELL Technologies).
All reprogrammed lines were tested negative for mycoplasma.
2.3. Sendai Reprogramming. Reprogramming of donors 5-7
was performed by Sendai reprogramming and carried out
by the company Takara Bio Inc. using a CytoTune-iPS 2.0
Sendai Reprogramming Kit (cat# A16517, Life Technolo-
gies). Clearance of the Sendai virus was tested by Q-PCR
using a TaqMan assay for Sendai virus. The Sendai virus level
was under the detection limit (CT ≥ 36) for all the generated
clones. Colonies were picked 3-4 weeks post transduction
and expanded in a Cellartis Feeder-Free DEF-CS Culture
System (cat# Y30017, Takara). All hiPSC lines were tested
negative for mycoplasma.
2.4. Maintenance of the Reprogrammed Cells. The repro-
grammed cell lines were cultured in 6-well plates (cat#
83.3920, Sarstedt), coated with Matrigel (cat# 354230,
Corning). The cells were maintained in mTeSR™1 media,
and media were changed every day. Once the dish was con-
fluent, just before colonies were in contact with each other,
the cells were split by using a Gentle Cell Dissociation
Reagent (cat# 7174, STEMCELL Technologies) by following
the instruction provided by the supplier. In brief, 1mL Gen-
tle Cell Dissociation Reagent was added to a well in a 6-well
plate and incubated (37°C) for 5min, followed by replacing
the Gentle Cell Dissociation Reagent by 1mL prewarmed
mTeSR™1 media and subsequently disrupting the colonies
by gently scraping the surface with a cell scraper. The cells
were split to a ratio between 1 : 6 and 1 : 10 depending on
the growth rate of the line and further cultivated until
confluency was reached again.
2.5. SSEA4+ Enrichment. All reprogrammed cell lines were
enriched for Anti-Stage-Specific Embryonic Antigen 4-
(SSEA-4-) positive cells by using magnetic cell isolation with
MicroBeads (cat# 130097855, Miltenyi Biotec) following the
guidelines provided by the supplier.
2.6. Classification of Reprogrammed Cell Lines. The repro-
grammed cell lines were qualitatively evaluated by using a
phase-contrast microscope and manually assigned to one of
the three morphology groups (stable colony, unstable class
1, and unstable class 2). Representative lines for each colony
morphology group were imaged using a Nikon TE2000 with
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a 10x objective. Immunocytochemistry analysis was per-
formed on a representative line for each colony morphology
group. Cells were cultured on glass coverslips and fixed in 2%
PFA for 15min. The immunofluorescence protocol was per-
formed following the guidelines provided by the suppliers.
The following antibodies were used: mouse anti-human
α-tubulin (1/100, cat# T5168, Sigma), rabbit anti-human
β-tubulin (1/500, cat# ab32572, Abcam); and the following
secondary antibodies were used: donkey anti-rabbit A647
(1/500, Molecular Probes) and donkey anti-mouse A594
(1/500, Molecular Probes). The nuclei were stained with
DAPI (cat# D1306, Molecular Probes). The samples were
mounted in ProLong Diamond Antifade Mountant Media
(cat# P36970, Life Technologies). The expression of β-
tubulin and α-tubulin was analyzed by using a Leica TCS
SP5 confocal microscope with a 40x objective. No specific
feature of the original data was obscured, eliminated, or
misrepresented.
2.7. Embryonic Body Formation. Embryonic bodies were gen-
erated by following the instructions of the AggreWell™800
Starter Kit (cat# 34850, STEMCELL Technologies). Briefly,
cells were harvested with the Gentle Cell Dissociation
Reagent and 1.2 million cells were plated in the Aggre-
Well™800 plates and incubated for 24 hours. The genera-
tion of embryonic bodies was facilitated by culturing the
embryonic bodies in Primate ES Cell Media (cat#
258RCHEMD001, Tebu Bio), the first 10 days in suspen-
sion plates (cat# 83.3920.500, Sarstedt) followed by 14 days
in 6-well plates (cat# 83.3920, Sarstedt), coated with Matrigel
(cat# 354230, Corning). The embryonic bodies were stained
for beta-III tubulin (TUJ1), smooth muscle actin (SMA),
and alpha-fetoprotein (AFP) by following the instructions
of the 3-germ layer immunocytochemistry kit (cat#
A25538, Thermo). The expression of TUJ1 (1/500), SMA
(1 : 100), and AFP (1 : 500) were analyzed by using a Leica
TCS SP2 microscope with a 40x objective, a Leica TCS SP5
confocal with a 40x objective, or a Leica TCS SP8 STED 3X
confocal microscope with a 100x objective.
2.8. Differentiation Experiments. Cells were directed towards
definite endoderm (DE) and primitive gut tube (PG) in
MCDB 131 medium (cat# 10372-019, Thermo Fisher Scien-
tific) with 1% 100x GlutaMAX, 1.5 g/L NaHCO3, 0.5% BSA,
and a 10mM final glucose concentration. Differentiation to
DE was done in 3 days by daily adding 100ng/mL Activin
A (cat# 120-14, PeproTech) and 0.3μM CHIR-99021
(reduced to 0 on the last day) (cat# S2924, Selleckchem). Fur-
ther differentiation to PG was done in 2 days by daily adding
0.25mM ascorbic acid (cat# A4544, Sigma) and 50ng/mL
FGF7 (cat# 100-19, PeproTech). The cells were analyzed by
flow cytometry.
2.9. Flow Cytometry Analysis. Cells were washed in Ca/Mg-
free PBS and incubated with TrypLE™ Select (cat# 12563011,
Thermo Fisher Scientific) 5 minutes in the incubator. The cell
suspension was washed in Ca/Mg-free PBS and then centri-
fuged 500 g for 4 minutes. The pellet was resuspended in
Ca/Mg-free PBS and incubated with the LIVE/DEAD Fixable
Dead Cell Near-IR Fluorescent Dye (cat# L10119, Invitrogen),
according to the manufacturer’s instructions. Next, the cells
were then fixed and permeabilized with the Fix/Perm Solution
Kit (cat# 554714, BD Biosciences) according to the manufac-
turer’s instructions. Cells were then stained with antibodies
and washed. For CD9 analysis (surface marker), cells were
stained with the antibody before fixation. A titration curve
was previously done to determine the volume of antibody to
add per tube of 106 cells: 1.5μL of AF488-POU5F1 antibody
(cat# BD560253, BD Biosciences), 1μL of APC-SOX17 anti-
body (cat# IC1924A, R&D), and 0.2μL of APC-CD9 antibody
(cat# BD341648, BD Biosciences) and the same amount of iso-
type control antibodies (cat# BD55772, BD Biosciences; cat#
IC108A, R&D; cat# IC003R, R&D). Data were analyzed with
FlowJo 10. Dead cells, debris, and doublets were excluded,
and after compensation, gating was determined on FL1/FL4
dot plots using Fluorescence Minus One (FMO) controls.
Unstained cells and isotype controls were run separately.
2.10. Global Proteomic Analysis
2.10.1. Sample Preparation with SDS Lysis Buffer and Filter-
Aided Sample Preparation (FASP). Cells were harvested with
TrypLE™ Select, washed twice with Ca/Mg-free PBS. The cell
pellet was resuspended in lysis buffer (4% SDS, 0.1M Tris,
pH 7.6), boiled for 7 minutes at 95°C, sonicated (3 × 30 sec-
onds) and centrifuged for 10 minutes at 14,000 g. Protein
concentration was measured with the Pierce™ BCA Protein
Assay Kit (cat# 232225, Thermo Fisher Scientific), and
volume corresponding to 25μg protein was further reduced
in 0.1M DTT and processed into peptides using filter-aided
sample preparation [18]. Prior to usage, all filters were
checked with a simple centrifugation step [19] in order to
exclude nonretaining protein membrane filters. The peptide
solutions were desalted with Oasis HLB 96-well μElution
plate (cat# 186001828BA, Waters) using 0.1% formic acid
(FA) and 80% acetonitrile (ACN)/0.1% FA as binding and
elution buffers, respectively. Eluted peptides were vacuum
dried and dissolved in 2% ACN, 1%FA prior to LC-MS
analysis.
2.10.2. LC-MS. For proteomic analysis, approximately 1μg
peptides per sample, dissolved in 2% ACN, 0.1% FA, were
injected into an Ultimate 3000 RSLC System (Thermo
Scientific, Sunnyvale, California, USA) connected online to
a Q-Exactive HF mass spectrometer (Thermo Scientific,
Bremen, Germany) equipped with EASY-Spray nano-
electrospray ion source (Thermo Scientific). The sample
was loaded and desalted on a precolumn (Acclaim PepMap
100, 2 cm × 75 μm ID nanoViper column, packed with 3μm
C18 beads) at a flow rate of 5μL/min for 5min with 0.1% tri-
fluoroacetic acid (TFA). Peptides were separated during a
biphasic ACN gradient from two nanoflow UPLC pumps
(flow rate of 200nL/min) on a 50 cm analytical column
(PepMap RSLC, 50 cm × 75 μm ID EASY-Spray column,
packed with 2μm C18 beads). Solvents A and B were 0.1%
FA (vol/vol) in water and 100% ACN, respectively. The
gradient composition was 5% B during trapping (5min),
followed by 5-8% B over 0.5min, 8–24% B for the next
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109.5min, 24–35% B over 25min, and 35–90% B over
15 minutes. Elution of very hydrophobic peptides and condi-
tioning of the column were performed during 15 minutes
isocratic elution with 90% B and 20 minutes isocratic condi-
tioning with 5% B.
The eluting peptides from the LC-column were ionized in
the electrospray and analyzed by the Q-Exactive HF. The
mass spectrometer was operated in the DDA mode (data-
dependent acquisition) to automatically switch between
full-scan MS and MS/MS acquisition. Instrument control
was through Q Exactive HF Tune 2.4 and Xcalibur 3.0. MS
spectra were acquired in the scan range 375-1500 m/z with
resolution R = 120,000 at m/z 200, automatic gain control
(AGC) target of 3e6, and a maximum injection time (IT) of
100ms. The 15 most intense eluting peptides above intensity
threshold 50 000 counts and charge states 2 to 5 were sequen-
tially isolated to a target value (AGC) of 1e5 and a maximum
IT of 100ms in the C-trap, and isolation width maintained at
1.6 m/z (offset of 0.3 m/z), before fragmentation in the HCD
(Higher-Energy Collision Dissociation) cell. Fragmentation
was performed with a normalized collision energy (NCE) of
28%, and fragments were detected in the Orbitrap at a
resolution of 15 000 at m/z 200, with first mass fixed at m/z
100. One MS/MS spectrum of a precursor mass was allowed
before dynamic exclusion for 20 s with “exclude isotopes” on.
Lock-mass internal calibration (m/z 445.12003) was used.
Furthermore, for spray and ion-source parameters, the ion
spray voltage was at 1800V, no sheath and auxiliary gas flow,
and the capillary temperature was at 260°C.
2.10.3. MaxQuant Analysis. The raw MS files were searched
in MaxQuant (v1.5.8.3) [20] using the default parameters
with the following exceptions: label-free quantification was
set to LFQ, minimum peptide length was set to 6 amino
acids, and the match-between-runs option was enabled.
The cellular protein levels were relatively quantified using
the MaxLFQ algorithm [21], and these intracellular levels
are presented as the relative LFQ intensity defined as
the normalized relative protein abundance compared
across the MS runs.
2.11. Postprocessing of the Proteomic Data. MaxQuant
normalized expression data (LFQ intensities) were log2
transformed. Reverse hits and contaminates were removed.
All samples had missing values which is common for low
abundant proteins; however, to avoid too many missing
values we only considered proteins with expression values
in at least 14/20 samples. For every protein, the fold changes
(FC) between stable and unstable were evaluated by subtract-
ing the median of the respective logarithm transformed
intensities. Next, we used Z-statistics [22] to evaluate the
significance of the FC (referred to as FC significance), and
FC p values < 0.05 were considered significant. The Perseus
software (v.1.6.2.3) was used to analyze and visualize the data
[23]. Principal component analysis (PCA) was performed in
Perseus and used to compare the reprogrammed lines using
the protein abundance. Missing values are incompatible
with this approach; therefore, we filtered the protein abun-
dance matrix to only contain valid values. Unsupervised hier-
archical clustering was performed in Perseus on z
-normalized abundance values. The parameters for cluster-
ing were average linkage and Euclidean correlation as dis-
tance measurement, prepossessed with k-means.
2.12. Pathway Analysis of the Proteomic Data. Pathway
analysis of the proteomic data was performed in Ingenuity
Pathway Analysis (IPA) software. Proteins being more abun-
dant in the unstable colony morphology group (n = 338) and
proteins being more abundant in the stable colony morphol-
ogy (n = 276) were analyzed in IPA to find networks and
upstream regulators in the two groups. We used log-
transformed z-normalized abundance values. “Select identifier
type” was set to “Gene symbol-human” and “Measurement
annotation for observation” was set to “expr log ratio.” We
performed a core analysis and used the default setting except
the following: 70 molecules per network and 25 networks
and all tissue and cell lines.
2.13. Receiver Operating Characteristic (ROC) Curves. ROC
curves were generated in GraphPad Prism by using the
default settings including a confidence interval of 95% calcu-
lated by using the Wilson/Brown method.
2.14. EMT Reversal Experiment Using Ligands. Cells were
seeded in wells in a 24-well plate, each well containing a
9mm cover slip subsequently coated with Matrigel. For the
first replicate, cells were harvested prior to the experiment
with the Gentle Cell Dissociation Reagent and 50 000 cells
were seeded in each well. For the second replicate, cells were
harvested with TrypLE™ Select and 100,000 filtered cells
were seeded in each well. In both experiments, the cells were
treated daily with ALX-270-445 (10, 25, and 50μM) or A83-
01 (0.2, 1, and 10μM) or SMURF1-i (2, 10, and 25μM) and
the cover slips were collected and fixed after 7 days. The
immunofluorescence protocol was performed following
directions provided by the supplier, and the following anti-
bodies were used: mouse anti-human E-cadherin (1/250,
cat# ab76055, Abcam) and rabbit anti-human vimentin
(1/100, cat# 5741, CST). The following secondary antibodies
were used: donkey anti-rabbit A647 and donkey anti-mouse
A594. The secondary antibodies were all from Molecular
Probes (dilution 1/500). The nuclei were stained with DAPI.
The samples were mounted in ProLong Diamond Antifade
Mountant Media. The expression of E-cadherin and vimen-
tin were analyzed by using the Andor Dragonfly 505 (Andor
Technologies, Inc.) confocal microscope with a 20x dry
objective (CFI Plan Apochromat Lambda 20x). The immu-
nofluorescence was quantified using the Imaris software
(v9.2.1). No specific feature of the original data was obscured,
eliminated, or misrepresented.
2.15. Statistical Analysis. Statistical analysis was performed in
Excel (v14.7.7) and GraphPad Prism (v7.0.0). A two-sided
t-test was used. p values < 0.05 were considered significant.
3. Results
3.1. Generation and Morphological Classification of
Reprogrammed Cell Lines. We used fibroblast cells isolated
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from seven donors’ skin biopsies to generate 20 reprogrammed
cell lines (Figure 1(a), supplementary table 1). Donor 1-4
fibroblasts were reprogrammed using episomal plasmids [17]
while donor 5-7 fibroblasts were reprogrammed using the
Sendai virus. Each donor generated 2-4 reprogrammed cell
lines each. After reprogramming, all lines presented a typical
pluripotent colony morphology. However, after subsequent
enrichment of SSEA4+ positive cells and further culturing,
four of the lines had changed their colony morphology to a
state with disintegrating colonies and two of the lines had
changed colony morphology to a monolayer state with
completely dispersed cells, referenced to in the remaining
part of this paper as class 1 and class 2 unstable lines,
respectively (Figures 1(a) and 1(b)). The cell lines were
maintained in the same culturing conditions and split when
they reached 80% confluence. At around passage 13, the lines
were qualitatively classified into the three colony morphology
groups (stable and unstable class 1 and 2) by the use of a
phase-contrast microscope (Figure 1(c)). Reprogrammed
lines generated from donors 1, 2, 5, and 7 were all classified
as lines showing stable colony morphology, whereas
reprogrammed lines generated from donors 3, 4, and 6
included some cell lines showing unstable colony morphology
and some cell lines showing stable colony morphology.
3.2. The Colony Morphology of Reprogrammed Cells Predicts
Differences in Spontaneous and Directed Differentiation
Capacity. We then assessed how the variation in colony
morphology of the reprogrammed cell lines affected the
spontaneous and directed differentiation capacity. First, we
assessed spontaneous differentiation by testing the capacity
to form embryonic bodies (EB) in 14 selected lines. We used
AggreWell plates for EB formation, followed by 10 days of
culture in suspension plates and 14 days on Matrigel-coated
plates, and subsequently analyzed the EB by immunohisto-
chemistry using markers for ectoderm (TUJ1), endoderm
(AFP), and mesoderm (SMA) (Figure 2(a)). Already at day
2 in suspension, a difference was noticeable, where EB from
stable colonies stayed as individual spheres, whereas EB from
unstable class 1 and class 2 formed aggregates (Figure 2(b)).
After completing the 29 days of the EB formation protocol,
we found, as expected, that all the reprogrammed lines with
stable colony morphology were able to form all three germ
layers (Figure 2(c)). In contrast, reprogrammed lines with
unstable class 1 morphology and unstable class 2 morphol-
ogy were only able to reliably form ectoderm. Two of the
lines (lines 6-A and 3-C) could only form ectoderm. Two of
the lines (lines 4-A and 4-C) could form ectoderm and meso-
derm, while one of the lines (line 3-B) could form ectoderm
and endoderm. Only one of the unstable class 1 lines (line
6-C) was able to form all three germ layers. An overview
showing immunohistochemistry images for the lines can be
found in supplementary figure 1.
Next, we investigated the directed differentiation capac-
ity using ligands that directed the reprogrammed lines
















                 # cell






























A B C D 
Stable colony
Unstable class 1 
Unstable class 2 
Classification based on morphology
(c)
Figure 1: Generation of 20 reprogrammed cell lines and their classification based on morphology. (a) A total of 20 lines were SSEA4+ enriched
and passaged >P10 and subsequently microscopically classified into one of the tree morphology groups; stable colony (14 cell lines), unstable
class 1 (4 cell lines), and unstable class 2 (2 cell lines). (b) In the upper panel, phase-contrast images illustrate a representative morphology
for the different groups and in the lower panel immunofluorescence images showing the organization of the structural proteins α-tubulin and
β-catenin. (c) An overview of the 20 reprogrammed lines, organized by donors. The generated lines from each donor are named with the





























1-C Stable colony x x x
3-A Stable colony x x x
4-B Stable colony x x x
5-A Stable colony x x x
5-B Stable colony x x x
6-B Stable colony x x x
7-A Stable colony x x x
7-B Stable colony x x x
4-C Unstable class 1 x x
6-A Unstable class 1 x
6-C Unstable class 1 x x x
3-B Unstable class 1 x x 
3-C Unstable class 2 x
4-A Unstable class 2 x x
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(e)
Figure 2: Colony morphology is associated with the capacity to form EB and directed differentiation. (a) An overview of the EB formation
protocol. (b) Phase-contrast images of the spontaneously differentiated EB at the following time points; Day 2 and Day 10 in suspension plates
and Day 2 and Day 14 onMatrigel-coated plates. (c) A score card of the ability to form the different embryonic germ layers for 14 selected cell
lines. The analysis was performed at the end of the protocol (Day 29) and analyzed by immunohistochemistry for the markers TUJ1
(ectoderm), AFP (endoderm), and SMA (mesoderm). (d) An overview of the directed differentiation protocol towards definite endoderm
(DE) and primitive gut tube (PG). (e) The directed differentiation capacity as measured with flow cytometry analysis for the pluripotency
marker POU5F1 and the DE marker SOX17 in line 7-B (stable colony), line 4-C (unstable class 1), and line 4-A (unstable class 2). There
were no SOX17+ cells in line 4-A at any of the time points.
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furthermore to primitive gut tube (PG stage) (Figure 2(d)).
One representative line from each colony morphology group
was analyzed by flow cytometry (3 replicates per line) at the
starting point, at the DE stage, and at the PG stage. In order
to analyze the capacity to exit the pluripotent state and enter
and exit the DE stage, we analyzed the cells by flow cytometry
at all three time points (d0, DE, and PG) for cells expressing
POU5F1 (pluripotency marker also known as OCT4) and
SOX17 (essential transcription factor in the formation and
maintenance of DE [24]) (Figure 2(e)). We found that
the reprogrammed line with stable colony morphology
had 99% ± 0:2 SD POU5F1+ cells at d0, dropping to
30% ± 11 SD at DE and 20% ± 4:8 SD at PG (Figure 2(e)).
As anticipated, SOX17 was undetectable at d0 and increased
to 80% ± 6:9 SD at the DE stage before dropping to 50% ± 26
SD at the PG stage. For the reprogrammed line with unstable
class 1 colony morphology, we observed a similar pattern,
albeit with only 83% ± 1:6 SD POU5F1+ cells at d0 and
71% ± 4:4 SD SOX17+ cells at the DE stage. Finally, for
the unstable class 2 colony morphology line, we found
93% ± 2:4 SD POU5F1+ cells at d0, and the level stayed
high at the DE stage (94% ± 2:4 SD) and at the PG stage
(95% ± 0:7 SD) with no observable SOX17+ cells at any
time point. Taken together, the unstable colony morphology
was associated with impaired directed differentiation capac-
ity and reduced capacity to form the three germ layers.
3.3. The Variable Colony Morphology Groups Show Distinctly
Different Proteomic Signatures. Global label-free proteomics
of the 20 reprogrammed lines yielded 6173 quantified pro-
teins, with an average of ~5000 quantified proteins in each
sample (Figure 3(a)). Proteins expressed in at least 14/20
samples (n = 5043) were analyzed by unsupervised clustering
(Figure 3(b)). We found that reprogrammed lines clustered
together based on colony morphology appearance and not
by reprogramming method or sex of the donor. However, it
should be noted that one of the unstable lines (line 3-B) clus-
tered within the stable colony morphology group, although
the line was classified as an unstable class 1 line. Next, we
looked at proteins expressed in all samples (n = 3833) and
performed a PCA analysis (Figure 3(c)). Again, we found that
reprogrammed lines clustered together based on colony mor-
phology, this time with a clear separation between samples
from stable and unstable colony morphology lines. However,
we noted that unstable class 1 colony morphology and unsta-
ble class 2 colony morphology samples did not separate from
each other. These groups were thus merged into one com-
mon group in the remaining global proteome comparison.
Next, we looked at differentially abundant proteins
(n = 614) comparing the stable group (14 cell lines) to the
unstable group (6 cell lines) (Figure 3(d)). Significant differ-
entially abundant proteins had by definition a p value <
0.05 and a fold change p value < 0.05. We identified 338
proteins being more abundant in the unstable colony
morphology group (supplement table 3), and we identified
the top molecular and cellular functions associated with
these proteins, as listed in Figure 3(e). Furthermore, in the
unstable group, we identified proteins well known as
markers for mesenchymal cells, including N-cadherin
(CDH2), fibronectin (FN1), vimentin (VIM), and matrix
metallopeptidase 14 (MMP14) (Figure 3(f)). We also
investigated whether we could detect protein markers for any
of the three germ layers in the unstable colony morphology
group. Endoderm markers (SOX17, GATA4, GATA6, and
EOMES) and mesoderm markers (TBXT, FOXF1) were not
identified in our data set. Ectoderm markers including nestin
(NES), RNA-binding protein Musashi homolog 1 (MSI1),
microtubule-associated protein 2 (MAP2), and glial fibrillary
acidic protein (GFAP) were identified, among which only
NES and MAP2 had a significantly higher abundance in the
unstable colony group (Figure 3(f)).
Similarly, we identified 276 proteins being more abun-
dant in the stable colony morphology group (supplement
table 2) and we identified the top molecular and cellular
functions associated with these proteins (Figure 3(e)).
Furthermore, we detected protein markers for pluripotency
including podocalyxin-like protein 1 (PODXL), developmental
pluripotency-associated 4 (DPPA4), and DNA (cytosine-5-)-
methyltransferase 3 beta (DNMT3B) (Figure 3(f)). We also
noted a significant higher abundance of E-cadherin
(CDH1) in the stable colony morphology group. Together
with the significant higher abundance of N-cadherin
(CDH2) in the unstable colony morphology group, our
observations are in line with a cadherin switch (increase of
CDH2 and a decrease of CDH1) previously described in
EMT events [25]. Figure 3(g) shows the ranked fold
changes for the individual proteins providing the signature
for both morphology groups.
3.4. Common Markers for Pluripotency Did Not Vary
Significantly between Reprogrammed Lines Showing Stable
and Unstable Colony Morphologies. Surprisingly, the abun-
dance of the common pluripotency markers sex-determining
region Y (SOX2) and octamer-binding transcription factor 4
(POU5F1) was not significantly more abundant in the stable
colony morphology group compared to the unstable colony
morphology group (Figure 4(a)), with p values of 0.22 and
0.69, respectively (not shown). Furthermore, we asked if other
common pluripotency markers had a higher abundance in the
stable colony morphology group compared to the unstable
colony morphology group, which could serve as a potential
marker for stable colony morphology. Based on well-known
pluripotency markers previously published [26, 27], we identi-
fied 33 out of a total of 49 markers in our data set and further
assessed the abundance of these 33 markers in stable and
unstable morphology groups (Figure 4(a)). Indeed, we identi-
fied that a subgroup of around ten proteins including CD9
antigen (CD9) and PODXL was more abundant in the stable
colony morphology group, with p values of 0.0003 and
0.0002, respectively. Next, the separation efficiency for
POU5F1, SOX2, PODXL, and CD9 to distinguish between
the two groups (stable and unstable) was evaluated by making
receiver operating characteristic (ROC) curves (Figure 4(b)).
Indeed, SOX2 and POU5F1 showed low ability to distinguish
between the two groups, with area under the curve (AUC)
values of, respectively, 0.62 and 0.5. In contrast, PODXL and
CD9 could distinguish between the groups, with AUC values
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Proteins more abundant in
unstable colony group (n = 338) 
      Proteins more abundant in
      stable colony group (n = 276)  
Molecular and cellular functions   #molecules
Cellular assembly and organization     133
Cellular function and maintenance     122
Cell morphology    102
Cellular movement    116
Cell to cell signaling and interaction      76
Molecular and cellular functions    #molecules
Amino acid metabolism 28
Small molecule biochemistry 38
Cell cycle 67
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data, we measured the levels of CD9 and POU5F1 by flow
cytometry in selected stable and unstable colony morphology
lines (Figure 4(c)). There was a tendency, although not signif-
icant, towards lower POUF5 and CD9 levels in the unstable
colony morphology lines.
3.5. Pathway Analysis Suggests TGFB-Induced EMT Events
in Reprogrammed Lines with Unstable Colony Morphology.
To identify upstream regulators in the unstable morphology
group, we performed pathway analysis using the IPA (Inge-
nuity Pathway Analysis) software tool. In this analysis, we
used the differentially abundant proteins (n = 614, displayed
in Figure 3(d)) and asked which upstream regulator pro-
teins could explain the emergence of this protein signature
in silico. The top scoring upstream regulators in the unsta-
ble morphology group were TCF7L2 followed by CTGF and
TGFB1 (Figure 5(a) and supplementary table 4). Since
TGFB is the major signalling pathway for inducing EMT
[28], we sought to focus on TGFB as an upstream regulator
in the unstable morphology group. The canonical TGFB
signalling is activated by ligands that act on TGFB receptors
with subunits ALK4, ALK5, and ALK7 [29] (Figure 5(b)).
SMAD2/3 is subsequently phosphorylated and together
with SMAD4 enters the nucleus to activate transcription
factors and regulate target genes. An alternative cascade
occurs though SMURF1-regulated RHOA degradation that
mediates EMT [30] (Figure 5(b)). In this case, the activated
receptor phosphorylates PAR6, thereby stimulating the
recruitment of SMURF1 and leading to tight junction
dissolution, which is a characteristic of EMT. In our
proteomic data set, several of the molecules involved in both
the canonical TGFB route to EMT and the alternative
SMURF-regulated route to EMT were identified and
displayed in the volcano plot (Figure 5(c)). For the canonical
TGFB signalling pathway, SMAD2 was found to be more
abundant in the unstable colony morphology group together
with downstream target molecules such as COL1A1 and
FN1. For the SMURF1-regulated route, SMURF1 itself was
found to be one of the most abundant proteins in the
unstable colony morphology group compared to the stable
colony morphology group (Figure 5(c)). Furthermore, we
have conflicting data as PAR6 was found to be less abundant
and RHOA was found to be more abundant in the unstable
colony morphology group. From these different protein
abundances, we hypothesize enhanced activity in the canonical














































































































































































Stable signature Unstable signature
(g)
Figure 3: Global proteomics of the 20 reprogrammed cell lines reveals different proteomic signatures for the different colony morphology
groups. (a) Workflow for the proteomic experiment analyzing the global proteome of 20 reprogrammed cell lines microscopically
classified into stable colony morphology (14 lines), unstable class 1 colony morphology (4 lines), and unstable class 2 colony morphology
(2 lines). The samples are cell lysates from the corresponding cell line. The samples were quantified using label-free proteomics, which
yielded ~5000 proteins in each sample. Raw values were log2 transformed, and fold changes (FC) between the combined unstable colony
morphology group (6 lines) and stable colony morphology group (14 lines) were calculated. Proteins with a p value < 0.05 and a
FC p value < 0.05 (n = 614) were regarded as being differentially abundant between the groups. (b) Unsupervised clustering analyses of the
20 reprogrammed lines based on proteins expressed in at least 14/20 samples (n = 5043) showing that the clusters tend to associate more
with morphology and less with donor sex and reprogramming methods. S = stable colony morphology; U = unstable colony morphology.
(c) Principal component analysis (PCA) of proteins expressed in all samples (n = 3833) shows a clear separation between stable colony
morphology (black circles) and unstable colony morphology (grey and white circles). (d) Unsupervised clustering analyses of the 614
differentially abundant proteins. The clustering analysis revealed two major clusters separated by colony morphology. (e) Tables
describing molecular and cellular functions of the protein being more abundant in the unstable colony morphology group (n = 338) and
the stable colony morphology group (n = 276). (f) A selection of differentially abundant proteins in the morphology groups. EMT markers
(VIM, MMP14, FN1, and CDH2) and ectoderm markers (NES, MAP2) were more abundant in the unstable colony morphology group
(U), whereas pluripotency markers (PODXL, DPPA4, DNMT3B, and CDH1) were more abundant in the stable colony morphology group
(S). Statistical analysis was performed with Mann-Whitney t-test. Significant differences are shown as ∗p < 0:05, ∗∗p < 0:01, ∗∗∗p < 0:001,
∗∗∗∗p < 0:0001, and ns p > 0:05. n/a = not a number. (g) Top differentially abundant proteins ranked by fold change (stable compared to
unstable). Only proteins with a p value < 0.05 were included in the ranking. The pluripotency markers DNMT3B, DPPA4, and SALL4, the
EMT marker FN1, and the ectoderm marker MAP2 are highlighted in green (up in the stable colony morphology signature) and red (up
in the unstable colony morphology signature).
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Figure 4: Variations in pluripotency markers and the ability to separate the stable colony morphology group from the unstable colony
morphology group. (a) A heat map of 33 commonly used pluripotency markers [26, 27] identified in our proteomic data set. The cluster
analysis was only applied on rows, not columns. The heat map revealed a group of 10 markers that were able to separate the two
morphology groups. (b) ROC curves for POU5F1, SOX2, PODXL, and CD9 when comparing the stable colony morphology group with
the unstable colony morphology group. (c) Flow cytometry analysis of the markers POU5F1 and CD9 in selected stable (S) and unstable
(U) lines.
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Upstream regulator Molecular type   Activation score
TCF7L2 Transcription regulator 3.71
CTGF Growth factor 3.15
TGFB1 Growth factor 3.07
MYC Transcription regulator –4.61
MYCN Transcription regulator –3.36
ATF4 Transcription regulator –3.08
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SMURF1-regulated route in the unstable colony morphology
group.
Trying to validate these findings experimentally, we
selected a reprogrammed line with unstable class 1 colony
morphology (line 4-C) previously identified with high
expression of EMT markers (Figure 3(f)) and exposed it to
TGFB inhibitors (ALX-270-445 and A83-01) and a SMURF1
inhibitor (Smurf1-i) to see whether these ligands could
reverse the EMT event which would be indicated by an
increase in the colony marker E-cadherin (CDH1) and a
decrease in the EMT marker vimentin (VIM) [31]. We
treated the line for seven days with each drug at three
different concentrations and quantified the level of vimentin
and E-cadherin by immunocytochemistry (Figure 5(d)).
Although there were observable alterations in the quantified
levels, none of the ligands led to significantly decreased levels
of vimentin or significantly increased levels of E-cadherin,
and we did not observe a reversal of colony morphology
(towards stable colony morphology, not shown).
4. Discussion
In this study, we used label-free quantitative proteomics to
compare reprogrammed cell lines displaying stable colony
morphology to lines with unstable colony morphology.
Colony morphology is typically considered an important cri-
terion for undifferentiated pluripotent cells and is a valuable
assessment in the daily routine in stem cell laboratories.
However, this assessment suffers frommanual and subjective
microscopic inspection and is therefore questionable in an
automated pipeline for benchmarking of cells [32].
By providing a first proteomic characterization of the
molecular signatures of reprogrammed cells displaying
different colony morphologies, our results demonstrate
proteome signature patterns robustly capturing the colony
morphology and provide an insight into the molecular mech-
anisms involved in spontaneous differentiation. The protein
signatures presented here could represent a base for next-
generation benchmarking of pluripotent cells, correlating
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Figure 5: Pathway analysis of the protein landscape between the unstable colony morphology group and the stable colony morphology group.
(a) IPA-generated tables of the top predicted upstream regulators in the unstable colony morphology group. (b) A model (modified
from [29, 30]) illustrating mechanistic factors involved in the EMT effect caused by TGFB signalling and the small molecules we
applied in the experiment that lead to the results illustrated in (d). (c) A volcano plot showing proteins being more abundant in
one of the groups (blue dots), where a selection of proteins related to EMT and TGFB signalling is highlighted in red. (d) An
illustration of the experiment where cells from unstable class 1 (line 4-C) were seeded on 9mm cover slips and treated for 7 days
with the ligands ALX-270-445, A83-01, or Smurf1-i. Graphs showing quantitative immunofluorescence (surface area) of vimentin
(EMT marker) and E-cadherin (colony marker) in line 4-C after treatment with the ligands ALX-270-445, A83-01, and SMURF1-i
at varying concentrations. The analysis was done by using the Andor Dragonfly 505 microscope and subsequently quantified by using
the Imaris software, where raw surface area measurements of vimentin and E-cadherin were normalized on nucleus count for each cover
slip. Expression is given as ratio to the median of the control samples (n = 8). Statistical analysis was performed with Mann-Whitney test.
Significant differences are shown as ∗p < 0:05.
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protein profiles with colony morphology, which is consid-
ered a critical indicator of true pluripotent cells.
In the unstable colony morphology group, we found
higher abundance of mesenchymal markers including
vimentin (VIM), N-cadherin (CDH2), and fibronectin
(FN1). This is in line with previous reports [25, 31, 33–36].
In fact, the presence of mesenchymal-like cells in colonies
that undergo spontaneous differentiating was first time
reported in 2001 [37]. Furthermore, epithelial to mesenchy-
mal transition (EMT) was subsequently identified and associ-
ated with spontaneous differentiation [33, 34]. However,
EMT markers in differentiating PSCs have mainly been
shown by immunohistochemistry and Q-PCR [25, 33, 35]
and also using RNA-seq [38] and DNA microarray [31, 36].
In our study, we show for the first time that mass
spectrometry-based proteomics can identify similar EMT
profile and also capture the broader molecular picture of
this event.
It is known that EMT can be induced via several path-
ways [28]; however, the mechanisms triggering EMT in stem
cells are not fully understood. Already in 2005, D’amour et al.
discovered an Activin A-induced EMT in the differentiation
to DE; however, it was not clear which signalling pathway
was involved [39]. Later in 2017, Li et al. showed that Activin
A-induced formation of DE includes an EMT event triggered
by TGFB signalling [38]. This is in line with our global
proteomic assay where the pathway analysis is suggestive
for a TGFB-induced event in the unstable colony morphol-
ogy group. We identified TGFB pathway molecules to be
more abundant (SMAD2, SMURF1, ROCK2, and RHOA)
as well as downstream target genes (COL1A1, VIM, and
FN1). In our attempt to reverse EMT, we tried to inhibit
the TGFB receptors by using the ligands ALX-270-445
(inhibits ALK 5 subunit) and A83-01 (inhibits ALK 4, 5,
and 7 subunits). We also attempted to inhibit SMURF1 as
this TGFB-related protein had a high abundance in the
unstable colony morphology group in our data. By using
the selected ligands, we observed an alteration in vimentin
and E-cadherin expression; however, a reversal of EMT indi-
cated by an increased level of E-cadherin and a decreased
level of vimentin was not observed. As EMT can be induced
via several pathways and crosstalk can occur [40], the role of
the molecules we are targeting can possibly be replaced by
other signals. Feng et al. showed for example in 2012 that
an activation of PKC is associated with EMT in stem cells,
and Kinehara et al. showed in 2014 that by using a PKC-
inhibitor the EMT was reversed [31].
The underlying reason for the dynamic change of the
PSC colony morphology is not fully understood. Epigenetic
memory and an incomplete reprogramming could be one
explanation [41]. Furthermore, the feeder-free system has
been reported to cause unwanted spontaneous differentiation
[37], especially when using Matrigel [42]. Both these findings
could explain the variation in our sample set. Cell competi-
tion was recently found to be a mechanism during repro-
gramming where elite cells overtake the cell population
[43]. Cell competition could also explain changing in colony
morphology at a later passage where differentiated cells out-
compete nondifferentiated cells. Also, variation in hiPSC
lines has been shown to be donor dependent [5, 44, 45];
our studies, however, showed that variations related to col-
ony morphology are not donor dependent, as three of the
donors (donors 3, 4, and 6) had lines classified to more than
one morphology group.
The differentiation potential associated with colony mor-
phology is an important aspect as this is a crucial function of
PSCs. In our study, we found that reprogrammed lines with
unstable colony morphology could form ectoderm; however,
the extent of endoderm and mesoderm formation was
varying. There have been some studies correlating different
classes of PSCs to differentiation capacity; however, most of
them have showed a successful formation of the three germ
layers in all classes or only tested a selection of qualified lines
[11, 12]. Only a few studies have showed varying differentia-
tion potential; for example, Chen et al. published in 2009 a
study where hESCs were classified in three morphology
groups and found that in vivo differentiation capacity, mea-
sured by teratoma formation in mice, differed for the classes
[6]. However, the hESC classes were based on expression
markers, not colony morphology. Also, Wakao et al. pub-
lished in 2012 a study where only one out of seven iPSC
classes could successfully form EB [13]. However, the iPSCs
were classified based on cell characteristics and not the over-
all colony morphology. To our knowledge, our study is
unique in classifying the reprogrammed lines (>P10) based
on overall colony morphology and correlation to EB forma-
tion capacity.
For the PSCs and regenerative medicine field, the safety
aspect is unavoidable. Changes and variations in PSC are
partly unpredictable, and it is important to evaluate the cells
routinely. As typical and common markers for pluripotency
have been questioned [13], more comprehensive automated
assays to benchmark cells are needed to ensure a sufficient
quality control. Our proteomic data show distinct proteomic
profiles for the colony morphology groups; hence, the prote-
omic analysis reflects the colony morphology and the PSC
status. In this study, we demonstrate the validity of using
proteomics to monitor reprogrammed lines and suggest that
it should be part of an automated assay to benchmark cells.
5. Conclusion
In this study, we classified 20 reprogrammed cell lines based
on colony morphology and subsequently tested their differ-
entiation capacity and analyzed their proteomic profiles
using mass spectrometry. We found that different defined
patterns of colony morphology were associated with distinct
proteomic profiles and different outcomes in differentiation
capacity. Finally, we provided insight into possible molecular
mechanisms involved in the formation of stable and unstable
colony morphologies during reprogramming.
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